To next ensure that our MUC1-targeted T cells retained effector function in the suppressive tumor microenvironment, we paired our CAR with a chimeric receptor designed to harness and invert the inhibitory effects of tumor-produced IL4. This evidence concerns the gene MUC1 and neoplasm.